Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Total Current Assets
All assets expected to be converted to cash or used up within one year.
Upstream Bio, Inc.NASDAQ: UPB
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 30.3% from a year ago
Total current assets stood at $316.28M at the end of Q1 FY2026, down 30.3% from a year earlier and down 10.1% from the prior quarter. Over 3 fiscal years it compounded at +167.8% a year.
Context
- Total current assets amounted to 99.4% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -30.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 351.8M USD
- Year-over-year change
- -26.6%
- 3-year CAGR
- +167.8%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 351.8M | -26.6% |
| FY2024 | 2024-12-31 | 479.16M | +309.6% |
| FY2023 | 2023-12-31 | 117M | +539.1% |
| FY2022 | 2022-12-31 | 18.31M | — |
Total Current Assets vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -30.3% is the lowest of 10, against a peer median of +36.4%.
- Total current assets amounts to 99.4% of total assets for UPB, versus a peer median of 97.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.1B USD | +117.9% | +132.0% | 100.0% | |
| Jun 2026 | $928.08M USD | +36.4% | -17.2% | 95.9% | |
| Mar 2026 | $850.82M USD | -2.0% | -16.9% | 81.6% | |
| Sep 2026 | $778.86M USD | +120.4% | -5.4% | 99.0% | |
| Mar 2026 | $730.16M USD | +129.8% | +72.5% | 97.7% | |
| Mar 2026 | $561.27M USD | +117.6% | +84.1% | 96.2% | |
| Mar 2026 | $471.18M USD | -14.1% | +2.5% | 99.7% | |
| Mar 2026 | $466.45M USD | -15.4% | -24.3% | 61.5% | |
UPBUpstream Bio, Inc. | Mar 2026 | $316.28M USD | -30.3% | +167.8% | 99.4% |
| Sep 2026 | €293.21M EUR | -13.0% | +21.5% | 99.4% | |
| Peer median (excluding UPB) | — | +36.4% | +2.5% | 97.7% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.